Increased AER reporting welcomed by Health Canada
National public health association Health Canada has backed a report which recommends closer monitoring of adverse reactions to Herbal Medicinal Products (HMP).
Archives for February 15, 2010
Hydroxycut liver problem link confirmed by study
A small study published in the American Journal of Gastroenterology has confirmed links between the herbal weight loss supplement Hydroxycut, and liver problems.
Science builds for Kyowa’s dipeptide for endurance performance
Supplementation with a ‘high tech’ amino acid dipeptide may enhance fluid regulation in healthy, active individuals during endurance and high intensity exercise, says a new study.
Do drink makers have stomach for anti-obesity fight?
Bravo! The beverage industry has responded enthusiastically to Mrs. Obama’s campaign to tackle childhood obesity - but there’d better be more than froth behind that sparkling rhetoric.
IADSA to focus on advocacy and emerging markets regulation
Regulatory harmonisation in Asian and Latin American countries coupled with tight monitoring of media content on dietary supplements to offset negative opinion will continue to be the focus of the international food supplements body in 2010.
Magnesium supplements may boost lung health for asthmatics
Daily supplements of magnesium may improve lung function in asthmatics, and improve their quality of life, says a new study from America.
Seaweed extract shows joint health promise
An extract from brown seaweed may reduce the symptoms of osteoarthritis by up to 52 per cent, suggests results from phase I and II clinical trials from Australia.
Provexis and DSM close to global rights deal
UK-based start-up Provexis has signed a Letter of Intent with its biggest shareholder, DSM, that will give the nutritional products division of the Dutch company exclusive global rights to Provexis’s tomato extract Fruitflow technology.
Glucosamine joint health opinion questioned by EC committee
At least one European Union member state has queried a recent reduced cartilage degeneration article 14 health claim submission that was turned down by EFSA partially because the studies submitted were not conducted on healthy populations.